Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVAREC trial of bevacizumab plus temozolomide in recurrent grade II/III glioma
NL-OMON43916Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioma, astrocytoma, Oligodendroglioma (OG) and 1 more comparing Temozolomide with Bevacizumab + temozolomide (2 arms). Primary endpoint: Overall survival at 12 months. Started Feb 2011; status: active, not recruiting.
02
Drugs
bevacizumabtemozolomide
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)oligoastrocytoma
Beyond the preview
Go deeper on NL-OMON43916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43916.